1. (a) An ATC shall maintain and make available educational materials about cannabis and CIP and their use to qualifying patients, their designated caregivers, their certifying providers, and visiting qualifying patients.
2. (b) Each ATC shall have an adequate supply of current educational materials available for distribution to registered qualifying patients and their designated caregivers, and visiting qualifying patients, including any materials supplied by the department to be made available.
3. (c) Educational materials shall be available for inspection by the department upon request.

4. (d) The educational materials shall include, at a minimum, information about the following:

   1. (1) Strains of cannabis, routes of administration, and their different effects in order to assist in the selection of prepared cannabis;
   2. (2) How to achieve proper dosage for different routes of administration with an emphasis on using the smallest amount of cannabis possible to achieve the desired effect, and the impact of potency;
   3. (3) Substance use disorder information on tolerance, dependence, and withdrawal, with an emphasis on cannabis use disorder;
   4. (4) Substance misuse signs and symptoms;
   5. (5) Referral information to substance use treatment programs;
   6. (6) Possible side effects from the use of cannabis for therapeutic purposes;
   7. (7) The extent to which the ATC’s cannabis and CIP meet or do not meet organic certification standards, other information concerning organic growing methods used by the ATC, and information concerning other methods used for cultivation and processing;
   8. (8) The warning information required to be included on the label as per He-C 402.19(d)(1)j. and k. and (d)(2)h;
   9. (9) The potential for contaminants in cannabis and CIP, the limitations of testing protocols in identifying such contaminants, and the associated health risks of consuming such contaminants, with an emphasis on cannabis flower and discouraging the inhalation of combusted cannabis particularly by immunocompromised patients;
   10. (10) Information about the risks of cannabis use during pregnancy and while breastfeeding, as outlined by the therapeutic cannabis medical oversight board, including the posting of an informational poster regarding the risks of cannabis use during pregnancy and while breastfeeding in a conspicuous location at the ATC’s dispensary locations;
   11. (11) Information regarding safe storage and disposal of cannabis, CIP, and paraphernalia to prevent accidental poisonings, including the contact information for the Northern New England Poison Control Center;
   12. (12) Information about the risks of cannabis use in adolescence as outlined by the therapeutic cannabis medical oversight board, including the posting of an informational poster on the risks of cannabis use in adolescence in a conspicuous location at the ATC’s dispensary locations; and
   13. (13) Therapeutic cannabis program rules and laws, including He-C 401, He-C 402, and RSA 126-X.
5. (e) The materials in (d) above shall be available in languages accessible to all patients served by the ATC including for the visually and hearing impaired, to the extent practicable.
6. (f) ATCs shall offer tracking sheets to qualifying patients and their designated caregivers to keep track of the strains of cannabis used, the form of prepared cannabis used, and the effects of cannabis and CIP used.

7. (g) ATCs shall keep a record for each qualifying patient, which includes:

   1. (1) The strains of cannabis dispensed, including potency; and
   2. (2) The form of prepared cannabis or CIP dispensed.

8. (h) In addition to the information in (g) above, the ATC shall collect data from each qualifying patient who is willing to provide it regarding:

   1. (1) Strains used and routes of administration as they relate to qualifying medical conditions and symptoms;
   2. (2) Any side effects experienced;
   3. (3) Therapeutic effectiveness;
   4. (4) Overall satisfaction with the ATC and therapeutic cannabis program in general; and
   5. (5) Other efficacy and use surveys, as directed by the department, upon a qualifying patient’s intake and at periodic and regular intervals.
9. (i) The ATC shall develop and implement a policy designed to increase the participation of qualifying patients in the activities described in (h) above.
10. (j) The data collected under (g) and (h) above shall be maintained using the qualifying patient’s registry identification number and shall be made available to the department upon request.

Source. #10731, eff 11-25-14; ss by #12653, eff 11-1-18; ss by #13673-A; eff 6-26-23